Lemonade Inc vs uniQure N.V. Ordinary Shares — how do they compare? Lemonade Inc trades at $43.82 (market cap $3.46B), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.48B). The key difference: Lemonade Inc is far larger — about 2.3× uniQure N.V. Ordinary Shares's market cap, and uniQure N.V. Ordinary Shares is trading nearer its 52-week high, Lemonade Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Lemonade Inc for 27 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| LMND | QURE | |
|---|---|---|
Market Cap | $3.46B | $1.48B |
Volume | 1,011,472 | 2,488,780 |
Sector | Financials | Health |
52-Week High | $96.57 | $70.59 |
52-Week Low | $43.86 | $9.03 |
Typical Hold Time | 27 Days | 0 Days |
Enterprise Value | $3.32B | $728.62M |
Signals from Pluang's Aura AI — not financial advice
Lemonade (LMND) trades at $43.86, down 2.86% on the day, with technical indicators showing bearish momentum despite recent earnings beats. The company continues to show strong revenue growth, with 2025 revenue reaching $738 million and improving margins, though it remains unprofitable with a net loss of $166 million. Recent expansion into Alaska and Kentucky, along with AI-driven efficiency improvements, supports the company's path toward EBITDA profitability by late 2026.
While Lemonade shows promising growth and margin improvement, the stock faces near-term technical pressure and persistent profitability challenges. The consensus price target of $67 offers significant upside potential, but investors must weigh expansion opportunities against ongoing losses and competitive pressures in the insurtech space.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes.
Read more on LMND →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →